Extended Data Fig. 5: Correlation of DNAM-1 and CD112 with response to anti-TIGIT or anti-LAG3 therapy. | Nature Cancer

Extended Data Fig. 5: Correlation of DNAM-1 and CD112 with response to anti-TIGIT or anti-LAG3 therapy.

From: Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial

Extended Data Fig. 5

a. DNAM 1 expression in circulating immune cells from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples (TIGIT Resp PreRx: n = 4, TIGIT Resp C1: n = 7, TIGIT Resp C2: n = 4; TIGIT NR Pre Rx: n = 4; TIGIT NR C1: n = 9, TIGIT NR C2: n = 2). Statistical test compares post Rx (C1 + C2) specimens from responders (n = 11) and non responders (n = 11) to anti-TIGIT therapy, 2-tailed Mann Whitney. b. CD112 expression in circulating immune cells from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples (TIGIT Resp PreRx: n = 4, TIGIT Resp C1: n = 7, TIGIT Resp C2: n = 4; TIGIT NR Pre Rx: n = 4; TIGIT NR C1: n = 9, TIGIT NR C2: n = 2). Statistical test compares post Rx (C1 + C2) specimens from responders (n = 11) and non-responders (n = 11) to anti-TIGIT therapy, 2-tailed Mann Whitney. c. DNAM-1 expression in effector memory CD8 + T cells and response to TIGIT blockade. DNAM 1 expression in circulating immune cells from biospecimens obtained from responding (Resp) or non-responding (NR) patients before (PreRx) after first (C1) or second cycle (C2) of therapy with anti-TIGIT antibody. Data points represent biologically independent samples. (TIGIT Resp PreRx: n = 4, TIGIT Resp C1: n = 7, TIGIT Resp C2: n = 4; TIGIT NR Pre Rx: n = 4; TIGIT NR C1: n = 9, TIGIT NR C2: n = 2). Statistical test compares post Rx (C1 + C2) specimens from responders (n = 11) and non-responders (n = 11) to anti-TIGIT therapy, 2-tailed Mann Whitney. d. DNAM-1 expression and response to anti-LAG3. Expression of DNAM-1/CD226 in CD8 and NK cells in blood and bone marrow and correlation with response to therapy in biospecimens from patients treated with anti-LAG3 antibody. Data points represent biologically independent samples; blood (Responder: n = 12, Non-Responder: n:19), bone marrow (Responder: n = 6, Non-Responder: n:11). No difference was observed in DNAM-1 expression on circulating or bone marrow CD8 or NK cells in patients who did or did not respond to anti-LAG3 therapy (p=non-significant 2 Tailed Mann Whitney). e. CD112 expression and response to anti-LAG3. Expression of CD112 in CD8 and NK cells in blood and correlation with response to therapy in biospecimens from patients treated with anti-LAG3 antibody. Data points represent biologically independent samples Data points represent biologically independent samples; blood (Responder: n = 12, Non-Responder: n:19), bone marrow (Responder: n = 6, Non-Responder: n:11). No difference was observed in CD112 expression on circulating or bone marrow CD8 or NK cells in patients who did or did not respond to anti-LAG3 therapy (p=non-significant 2 Tailed Mann Whitney). MMI: median metal intensity. Box plots represent median with Q1-Q3 and error bars as min-max.

Source data

Back to article page